Company Overview
Epigenic Therapeutics, established in 2021 and located in the China (Shanghai) Pilot Free Trade Zone, stands at the forefront of biotechnology innovation, specializing in next-generation gene modulation therapies. The company is dedicated to pioneering treatments for a wide array of diseases such as metabolic, cardiovascular, viral hepatitis, ocular, oncology, and rare diseases. Utilizing its proprietary EPIREG® platform, Epigenic Therapeutics integrates advanced artificial intelligence algorithms with CRISPR-Cas components to modulate gene expression precisely without altering the DNA sequence.
Key Technologies and Innovations
Epigenic Therapeutics leverages its Epigenetic Modulator platform, where nuclease-inactivated dead Cas proteins and epi-enzymes are employed to exert precise control over gene expression. Their approach circumvents DNA cutting or nicking, elevating the safety and therapeutic potential of their methodologies. Their patented lipid nanoparticle (LNP) delivery systems further ensure high efficiency and safety in delivering therapeutic compounds to specific cells and tissues, amplifying their potential in the treatment of chronic diseases.
Financial Background
In 2023, Epigenic Therapeutics raised $32 million in Series A funding, directing these resources toward advancing its epigenome medicines into clinical stages. Prior to this, the company had accumulated $20 million in angel and pre-A funding in 2022, fortifying its financial foundation to propel forward with its cutting-edge gene editing technologies.
Leadership Team
The leadership of Epigenic Therapeutics is spearheaded by CEO and Co-founder Bob (Bao-Hong) Zhang, noted for his visionary oversight and extensive R&D experience. Xinyu (Tom) Huang serves as the Chief Operating Officer and Head of CMC, while Qianchao (Alex) Wu guides Business Development. Zhiwei Lu, specializing in drug delivery systems, completes this dynamic team, contributing to technological innovation and strategic growth.
Contact Information
- Address: Floor 5&6, Unit 1, Building 4, 160 Basheng Road, China (Shanghai) Pilot Free Trade Zone
- Email: Partnering@epigenictx.com
Strategic Vision
Epigenic Therapeutics is dedicated to developing safe and sustainable epigenetic therapies to enhance patient quality of life globally. They aim to lead the field in gene regulation-based biotherapeutics, driving advancements to tackle complex medical challenges. Their core values embrace talent, life dedication, excellence, and innovation. Their active participation in industry innovation hubs like the Bayer Co. Lab underscores their strategic commitment to leadership in epigenetic therapy.
Key Competitors
Beam Therapeutics
- Headquarters: Cambridge, Massachusetts, USA
- Key Personnel: John Evans (CEO), Giuseppe Ciaramella (CSO)
- Focus: Beam Therapeutics is focused on precision genetic medicines via CRISPR and prime editing. Their method involves single nucleotide modifications without DNA cutting, enhancing genetic alteration specificity.
- Achievements: Secured approximately $1 billion in pre-IPO venture funding and an additional $180 million through a 2020 IPO. Collaborated with Pfizer in January 2022 for rare disease therapies development.
Korro Bio
- Headquarters: Cambridge, Massachusetts, USA
- Key Personnel: Ram Aiyar, Ph.D., MBA (CEO & President), Kemi Olugemo, M.D., FAAN (Chief Medical Officer)
- Business Focus: Specializes in RNA therapies, with techniques for RNA editing to modulate biological pathways and address both rare and widespread genetic diseases.
- Mission: Aims to deliver transformative genetic medicines informed by human genetics and disease biology.
eGenesis
- Headquarters: Cambridge, Massachusetts, USA
- Key Personnel: Mike Curtis, Ph.D. (President & CEO), Jennifer Bergheiser (Chief Business Officer)
- Core Technology: Utilizes multiplex gene editing and genome engineering to create human-compatible organs for transplantation, addressing global transplant shortages.
- Initiatives: Innovating in kidney and islet cell transplantation.
Nutcracker Therapeutics
- Location: Pennsylvania, USA
- Overview: Develops mRNA therapeutics through an advanced platform, facilitated by high-precision biosynthesis and engineering. Known for their GMP-in-a-box approach, reducing costs and cycle times for RNA therapeutics.
EdiGene
- Headquarters: Beijing, China
- Business Domain: Leverages genome editing technologies for drug discovery and novel therapeutics. Primarily targets transformative solutions for serious diseases, including hematopoietic issues and cancer.
